Frank Lavernia, MD, Talks About the Reduced Risk of MACE With GLP-1 RAs - MD Magazine
Despite the efforts to increase the affordability of GLP-1 receptor agonists cost-effectiveness is still a barrier for many patients living with diabetes looking for effective therapies.
Despite the efforts to increase the affordability for GLP-1 receptor agonists (RAs), cost-effectiveness is still a barrier for many patients living with diabetes looking for effective therapies. Howe… [+1438 chars]
Read More
Other Stories in Health
- Dosa saree, Idli shirt and a pani puri watch? AI turns desi food into fashion
- Where and why men die younger: global data breaks it down
- 8 Best Foldable Rowing Machines, According to Editors and Certified Trainers
- Strawberry Lemon Cream Crepes {Grain-Free Options Included}
- What predicts belief in the afterlife? A massive global study has answers
- Getting active in midlife may boost brain resilience to Alzheimer’s
- May 2025 Cooking Challenge
- May 2025 Cooking Challenge
- TDP-43 dysfunction in brain blood vessels may drive Alzheimer's and ALS progression
.png)
